加巴喷丁类药物用于慢性腰痛的有效性与安全性:随机对照试验的系统评价与Meta分析
该系统评价纳入8项随机对照试验,评估加巴喷丁类药物对成人慢性腰痛(病程>3个月)的疗效与安全性。加巴喷丁对比安慰剂疼痛改善极小(MD=0.22单位,95%CI[-0.5至0.07]),普瑞巴林对比其他镇痛药时其他镇痛药组改善更优(MD=0.42单位,95%CI[0.20至0.64]),且加巴喷丁组头晕、乏力、思维困难、视觉障碍等不良事件更常见。作者认为现有证据有限,需大型高质量试验进一步明确。
要点
- 加巴喷丁对比安慰剂疼痛改善极小,MD=0.22单位,95%CI[-0.5至0.07],GRADE证据质量极低。
- 普瑞巴林对比其他镇痛药,其他镇痛药组改善更优,MD=0.42单位,95%CI[0.20至0.64],GRADE证据质量极低。
- 加巴喷丁组头晕、乏力、思维困难、视觉障碍报告率高于安慰剂组,无死亡或住院报告。
核心结论
- 现有关于加巴喷丁类药物用于慢性腰痛的证据有限,显示存在显著不良事件风险而无任何已证实的获益。
- 鉴于缺乏疗效、相关风险与费用,加巴喷丁类药物用于慢性腰痛需谨慎。
- 需要大型高质量试验以更明确地指导该问题。
研究设计与样本
- 系统评价与Meta分析,检索MEDLINE、EMBASE和Cochrane数据库自建库至2016年12月20日。
- 纳入报告加巴喷丁类药物用于治疗成人慢性腰痛(病程>3个月)的随机对照试验,由配对评价者独立完成研究选择与数据提取。
- 共纳入8项研究,按干预与对照分为3组分析;结局指标以疼痛缓解和安全性为主要结局,参照Initiative on Methods, Measurement and Pain Assessment in Clinical Trials指南。
- 对3项及以上研究报告的结局进行Meta分析,效应量以均数差(MD)或风险比(RR)及其95%置信区间(CI)表示,I²表示异质性可解释的效应估计变异百分比,采用GRADE评估证据质量。
主要发现
- 加巴喷丁对比安慰剂(3项研究,n=185)疼痛改善极小,MD=0.22单位,95%CI[-0.5至0.07],I²=0%,GRADE证据质量极低。
- 普瑞巴林对比其他类型镇痛药(3项研究,n=332),其他镇痛药组改善更优,MD=0.42单位,95%CI[0.20至0.64],I²=0,GRADE证据质量极低。
- 普瑞巴林作为辅助用药的研究(n=423)因异质性未合并,其中最大的一项研究显示在他喷他多基础上加用普瑞巴林无获益。
- 无死亡或住院报告;对比安慰剂,加巴喷丁组更常报告头晕(RR=1.99,95%CI[1.17至3.37],I²=49)、乏力(RR=1.85,95%CI[1.12至3.05],I²=0)、思维困难(RR=3.34,95%CI[1.54至7.25],I²=0)和视觉障碍(RR=5.72,95%CI[1.94至16.91],I²=0)。
- 头晕、乏力、思维困难、视觉障碍的需害人数(NNH)及95%CI分别为7(4至30)、8(4至44)、6(4至15)、6(4至13);头晕和乏力的GRADE证据质量极低,思维困难为低,视觉障碍为中等。
关键数值与推荐
- 慢性腰痛终生患病率在51%至80%之间。
- 加巴喷丁对比安慰剂疼痛MD=0.22单位,95%CI[-0.5至0.07],I²=0%,GRADE证据质量极低。
- 普瑞巴林对比其他镇痛药MD=0.42单位,95%CI[0.20至0.64],I²=0,GRADE证据质量极低。
- 加巴喷丁对比安慰剂不良事件:头晕RR=1.99,95%CI[1.17至3.37],I²=49;乏力RR=1.85,95%CI[1.12至3.05],I²=0;思维困难RR=3.34,95%CI[1.54至7.25],I²=0;视觉障碍RR=5.72,95%CI[1.94至16.91],I²=0。
- 需害人数(NNH)及95%CI:头晕7(4至30)、乏力8(4至44)、思维困难6(4至15)、视觉障碍6(4至13)。
临床怎么用
- 作者认为,鉴于缺乏疗效、相关风险与费用,加巴喷丁类药物用于慢性腰痛需谨慎。
- 作者指出需要大型高质量试验以更明确地指导该问题。
局限性
- 现有关于加巴喷丁类药物用于慢性腰痛的证据有限。
- 头晕和乏力的GRADE证据质量极低,思维困难为低,视觉障碍为中等。
- 少数研究报告了功能与情绪改善且显示无显著改善。
- 普瑞巴林作为辅助用药的研究因异质性未合并。
- 需要大型高质量试验以更明确地指导该问题。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Chronic Low Back Pain (CLBP) is very common, with a lifetime prevalence between 51% and 80%. In majority, it is nonspecific in nature and multifactorial in etiology. Pregabalin (PG) and Gabapentin (GB) are gabapentinoids that have demonstrated benefit in neuropathic pain conditions. Despite no clear rationale, they are increasingly used for nonspecific CLBP. They necessitate prolonged use and are associated with adverse effects and increased cost. Recent guidelines from the National Health Service (NHS), England, expressed concerns on their off-label use, in addition to the risk of misuse. We aimed to assess the effectiveness and safety of gabapentinoids in adult CLBP patients. METHODS: Electronic databases of MEDLINE, EMBASE, and Cochrane were searched from their inception until December 20th, 2016. We included randomized control trials reporting the use of gabapentinoids for the treatment of CLBP of >3 months duration, in adult patients. Study selection and data extraction was performed independently by paired reviewers. Outcomes were guided by Initiative on Methods, Measurement and Pain Assessment in Clinical Trials guidelines, with pain relief and safety as the primary outcomes. Meta-analyses were performed for outcomes reported in 3 or more studies. Outcomes were reported as mean differences (MDs) or risk ratios (RRs) with their corresponding 95% confidence intervals (CIs), and I2 in percentage representing the percentage variability in effect estimates that could be explained by heterogeneity. GRADE (Grading of Recommendations Assessment, Development, and Evaluation) was used to assess the quality of evidence. RESULTS: Out of 1,385 citations, eight studies were included. Based on the interventions and comparators, studies were analyzed in 3 different groups. GB compared with placebo (3 studies, n = 185) showed minimal improvement of pain (MD = 0.22 units, 95% CI [-0.5 to 0.07] I2 = 0%; GRADE: very low). Three studies compared PG with other types of analgesic medication (n = 332) and showed greater improvement in the other analgesic group (MD = 0.42 units, 95% CI [0.20 to 0.64] I2 = 0; GRADE: very low). Studies using PG as an adjuvant (n = 423) were not pooled due to heterogeneity, but the largest of them showed no benefit of adding PG to tapentadol. There were no deaths or hospitalizations reported. Compared with placebo, the following adverse events were more commonly reported with GB: dizziness-(RR = 1.99, 95% CI [1.17 to 3.37], I2 = 49); fatigue (RR = 1.85, 95% CI [1.12 to 3.05], I2 = 0); difficulties with mentation (RR = 3.34, 95% CI [1.54 to 7.25], I2 = 0); and visual disturbances (RR = 5.72, 95% CI [1.94 to 16.91], I2 = 0). The number needed to harm with 95% CI for dizziness, fatigue, difficulties with mentation, and visual disturbances were 7 (4 to 30), 8 (4 to 44), 6 (4 to 15), and 6 (4 to 13) respectively. The GRADE evidence quality was noted to be very low for dizziness and fatigue, low for difficulties with mentation, and moderate for visual disturbances. Functional and emotional improvements were reported by few studies and showed no significant improvements. CONCLUSIONS AND RELEVANCE: Existing evidence on the use of gabapentinoids in CLBP is limited and demonstrates significant risk of adverse effects without any demonstrated benefit. Given the lack of efficacy, risks, and costs associated, the use of gabapentinoids for CLBP merits caution. There is need for large high-quality trials to more definitively inform this issue. TRIAL REGISTRATION: PROSPERO CRD42016034040.
引用
- Shanthanna H, Gilron I, Rajarathinam M, et al. Benefits and safety of gabapentinoids in chronic low back pain: A systematic review and meta-analysis of randomized controlled trials. PLoS Med. 2017. PMID: 28809936. doi:10.1371/journal.pmed.1002369
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。